Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

BASKING RIDGE, N.J., Nov. 16, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, Ph.D., Duke University Medical Center, presented an abstract at the AHA Scientific Sessions meeting on November 16, 2010 at 10:45 a.m. CST in Chicago, IL.

The abstract, entitled "RB006, a Direct Factor IX Inhibitor Results in Consistent and Near Complete Inhibition of Factor IX in Patients with Acute Coronary Syndromes: A RADAR Pharmacokinetic and Pharmacodynamic Substudy," evaluated the appropriateness of the selected dose of pegnivacogin (a.k.a. RB006) for use in patients with Acute Coronary Syndromes.  RB006 is part of the REG1 anticoagulation system.

Regado's ongoing Phase 2b clinical trial titled: "Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome," (a.k.a. RADAR) is a partially blinded study currently enrolling 800 patients in more than 90 centers worldwide.  Patients were randomly allocated [4:1] to receive open-label RB006 or unfractionated heparin prior to catheterization and underwent various levels of double blind reversal at the end of the procedure.  This substudy, conducted in the open label portion of RADAR, included thirty patients, 20 of whom had not received recent unfractionated heparin.  It assessed PK/PD measurements just prior to and 10 minutes after dosing with RB006.  PK/PD assessments were also made, both prior to and after cardiac catheterization and before blinded dosing of anivamersen (a.k.a. RB007), RB006's complementary active control agent.  The objective was to evaluate the appropriateness of the selected RB006 dose.  
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... The Judicial Panel on Multidistrict Litigation (JPML) ... centralize Inferior vena cava (IVC) Filter lawsuits filed against ... have already been centralized by the JPML. ... risk for a pulmonary embolism. The filters are designed ... Claims against Bard and Cook involve incidents of retrievable ...
(Date:7/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/h85dj3/pharmaceutical ) ... Market by Packaging Type, by Raw Material, by Drug ... Forecasts to 2020" report to their offering. ... is estimated to reach above $80 Billion by 2020 ... show a steady growth rate in the coming years. ...
(Date:7/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hmjqff/global_wound_care ) has ... Care Markets (Twelve Country Analysis: Germany, France, Italy, ... Brazil, Australia, South Korea)" report to their ... competitive market summary. The wound care market is ... product maturity. Several of the products within the ...
Breaking Medicine Technology:IVC filter litigation continues; law firm provides free information to IVC filter patients 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 2Pharmaceutical Packaging Market by Packaging Type, Raw Material & Drug Delivery Type - Forecasts to 2020 for the $80 Billion Industry 3Global Wound Care Markets 2015 2
... Blood fluoride levels were significantly higher in patients with ... in Biological Trace Element Research (April 2009). ... children and young adults.Randhu and colleagues measured serum fluoride ... patients. Group one had osteosarcoma, group two had non-osteosarcoma ...
... 29 Stallergenes S.A.,announces the release of the first ... on a sublingual house dust mite desensitization tablet. , ... the outcome of this study, which is the first,large ... mites allergen in,treating perennial allergic rhinitis. Furthermore, the unexpected ...
Cached Medicine Technology:Another Study Links Fluoride to Bone Cancer 2Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 2Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 3Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet 4
(Date:7/29/2015)... ... ... Join Luz Delia Gerber and Abbi Ferrin as they share their empowering message ... body actually works. A state of mindfulness allows one to be present and more ... forge this new relationship with their bodies. , Abi Ferrin has a passion for ...
(Date:7/29/2015)... ... ... Ticket Down is a reliable source of authentic tickets for the international friendly ... international soccer schedule of matches played on American soil continues to grow each year. ... world’s greatest teams, Brazil, will travel to North America to compete with the United ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the ... expiring November 30, 2019, during its recent meeting. , The Commission received renewal ... program’s compliance with the NCCA’s Standards for the Accreditation of Certification Programs. ...
(Date:7/29/2015)... ... July 29, 2015 , ... On July 26th the ... FDA for nicotine laced liquid products. Their report says cigarette use has decreased ... are particularly troublesome to addiction professionals as many of the candy flavors available ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Campbell Agency has once again teamed up with Stillwaters Cancer Support Services and ... their families. Stillwaters provides individual and family counseling, support groups, workshops and educational ...
Breaking Medicine News(10 mins):Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3
... under the responsibility of Marc Peschanski, director of ... stem cells and their therapeutic applications, aimed ... this field, with input from 17 renowned specialists ... stem cells, mesenchymatic, hematopoetic, and organ stem cells ...
... completed its acquisition of BioVeris. Roche signed the ... on April 4, 2007. ,This ... Electrochemiluminescence (ECL) technology and can expand its immunochemistry ... market segments such as life sciences research, life ...
... bitten and injured by a jackal in Bihar's Gopalganj district, ... to treat the patients. ,In the ... - including women and children - in half a dozen ... km from here. ,The injured are being treated ...
... to introduce organic farming in India with the help ... organic village will be set up in each of ... Ngodup Dorje, head of the agriculture and cooperative division ... villages will receive all inputs in the process of ...
... on drugs has officially declared Britain the cocaine capital of ... over 900,000 Britons buy cocaine, which means the country has ... addition, Britain's 350,000 heroin users are the largest number in ... from the UN's Office on Drugs and Crime also said ...
... among prisoners than among the general population of Thailandone study, ... that 25% of prisoners who agreed to be tested were ... the national population. ,But Thailands prisons, say Ford ... severe budgetary constraints that impede the effective delivery of HIV ...
Cached Medicine News:
HME only...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
Medicine Products: